TMS Co Ltd
TSE:4891
Intrinsic Value
TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. [ Read More ]
The intrinsic value of one TMS Co Ltd stock under the Base Case scenario is 80.85 JPY. Compared to the current market price of 242 JPY, TMS Co Ltd is Overvalued by 67%.
Valuation Backtest
TMS Co Ltd
Run backtest to discover the historical profit from buying and selling TMS Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
TMS Co Ltd
Current Assets | 3.2B |
Cash & Short-Term Investments | 3.1B |
Receivables | 31.1m |
Other Current Assets | 115.6m |
Non-Current Assets | 20.6m |
PP&E | 10.9m |
Intangibles | 3.3m |
Other Non-Current Assets | 6.5m |
Current Liabilities | 69.8m |
Accrued Liabilities | 46.8m |
Other Current Liabilities | 23m |
Non-Current Liabilities | 1k |
Other Non-Current Liabilities | 1k |
Earnings Waterfall
TMS Co Ltd
Revenue
|
0
JPY
|
Operating Expenses
|
-674m
JPY
|
Operating Income
|
-674m
JPY
|
Other Expenses
|
2m
JPY
|
Net Income
|
-672.1m
JPY
|
Free Cash Flow Analysis
TMS Co Ltd
Profitability Score
Profitability Due Diligence
TMS Co Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
TMS Co Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
TMS Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
TMS Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
TMS Co Ltd
According to Wall Street analysts, the average 1-year price target for TMS Co Ltd is 775.2 JPY with a low forecast of 767.6 JPY and a high forecast of 798 JPY.
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TMS Co., Ltd. engages in the research and development of pharmaceutical products and medical devices. The company is headquartered in Fuchu-Shi, Tokyo-To and currently employs 8 full-time employees. The company went IPO on 2022-11-22. The firm conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
Contact
IPO
Employees
Officers
The intrinsic value of one TMS Co Ltd stock under the Base Case scenario is 80.85 JPY.
Compared to the current market price of 242 JPY, TMS Co Ltd is Overvalued by 67%.